Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: Report of five clinical cases;L'amphotéricine B liposomale en prophylaxie secondaire chez les patients VIH+ atteints de leishmaniose viscérale: À propos de cinq cas

Pathologie Biologie

Volumn 52, Issue 2, 2004, Pages 66-75

  Montana, M ^a   Chochoi, N ^a   Monges, P ^a   Ravaux, I ^a   Faraut, F ^b   Gensollen, S ^a   Bongrand, M C ^a   Timon David, P ^a   Gallais, H ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Amphot ricine B; Amphotericin B; HIV; Leishmaniose visc rale; Liposomes; VIH+; Visceral leishmaniasis

Indexed keywords

ABACAVIR; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; MEGLUMINE ANTIMONATE; NELFINAVIR; RITONAVIR; STAVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EVALUATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; PROPHYLAXIS; STANDARDIZATION; VISCERAL LEISHMANIASIS;

ADULT; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; DRUG COMBINATIONS; DRUG EVALUATION; FEMALE; HIV INFECTIONS; HUMANS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RECURRENCE; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 1542361496     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2003.09.012     Document Type: Article

References (40)

1. Rapport OMS no 116 révisé Mai 2000 available from: URL: http://www.who.int/inf-fs/fr/am116.htlm.
2. Basset D, Pratlong F, Ravel C, Puechberty J, Dereure J, Dedet JP : « Les leishmanioses déclarées en France en 1999 », available from: URL: http://www.invs.sante.fr/beh/2001/05/arde1041.htm.
3. Gangneux J.P. « Traitement de la leishmaniose viscérale : modalités récentes » La presse médicale. 1999;28-37.
4. Gradoni L., Bryceson A., Desjeux P. "Treatment of mediterranean visceral leishmaniasis" Bulletin of World health organization. 73:(2):1995;191-197.
5. Lopez-Velez R., Perez-Molina J.A., Guerrero A., Baquero F., Villarrubia J., Escribano L., et al. "Clinicoepidemiologic characteristics, pronostic factors, and survival analysis of patients coinfected with HIV and Leishmania in an area of Madrid" Am J Trop Med Hyg. 58:(4):1998;436-443.
6. Alvar J., Canavate C., Gutierrez-Solar B., Jimenez M., Laguna F., Lopez-Velez:, et al. "Leishmania and human immunodeficiency virus coinfection: the first 10 years" Clinical Microbiology Reviews. 10:1997;298-319.
7. Agostoni C., Dorigoni N., Malfitano A., Caggese L., Marchetti G., Corona S., et al. "Mediterranean leishmaniasis in HIV-infected patients: epidemiological, clinical and diagnostic features of 22 cases" Infection. 26:(2):1998;93-99.
8. Mastroianni C.M., d'Ettore G., Forcina G., Corpolongo A., Dell'Isola S., Lichtner M., et al. "Long term remission of HIV-associated visceral leishmaniasis after initiation of potent combination antiretroviral treatment: report of two cases" J Infect. 40:(1):2000;94-96.
9. Marlier S., Menard G., Gisserot O., Kologo K., Jaureguiberry J.P. "Leishmaniasis and human immunodeficicency virus :an emerging co-infection?" Med Trop. 59:(2):1999;193-200.
10. Vidal 2002.
11. Montalban C., Calleja J., Enrice A., et al. "Visceral leishmaniasis in patients infected with human immunodeficiency virus" J Infected. 21:1990;261-270.
12. Altes J., Salas A., Riera M., et al. "Visceral leishmaniasis :another HIV-associated opportunistic infection ? Report of eight cases and review of litterature" AIDS. 50:1991;201-207.
13. Laguna F., Adrados M., Alvar J., et al. "Visceral leishmaniasis in patients infected with the human immunodefiency virus" Eur J Clin Microbiol Infect Dis. 16:1997;898-903.
14. Angarano G., Mappi P., Coppola S.L., Cavaliere R.L. "Itraconazole as maintenance therapy for visceral leishmaniasis in HIV infected patients" Eur J Clin Microbiol Infect Dis. 17:1998;365-367.
15. Behre N., Wolday D., Hailu A., Abraham Y., Ali A., Desjeux P., et al. "HIV viral load and response to antileishmanial chemotherapy in co-infected patients" Aids. 13:(14):1999;1921-1925.
16. Laguna F., Lopez-Velez R., Pulido F., Salas A., Torre-Cisneros J., Torres E., et al. "Treatment of visceral leishmaniasis in HIV infected patients : a randomized trial comparing meglumine antimoniate with amphotericin B" AIDS. 13:(9):1999;1063-1069.
17. Faraut F., Piarroux R., Deniau M., Giusiano B., Marty, Michel G., et al. "In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate : a study of 37 strains collected from patients with visceral leishmaniasis" Antimicrobial Agents and Chemotherapy. 41:(4):1997;827-830.
18. Rosenthal E., Marty P., Poizot-Martin I., et al. "Visceral leishmaniasis and HIV-1 co-infection in southern France" Trans R Soc Trop Me Hyg. 89:1995;159-162.
19. Borelli P, Imperato A, Murdaca G, Scudeletti M: "Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV", Ann Ital Med Int, 15(2), 169-71.
20. Hamour A.A., Skelly R., Jowitt S.N., Wilson G.E., Curry A., Wilkins E.G.L., et al. "Visceral leishmaniasis in two patients with HIV-1 infection : atypical features and response to therapy" J Infect. 26:(2):1998;217-220.
21. Blancard A., Monges P., Lacarelle B., Denis J.P., Bongrand M.C., Penot-Ragon C.H., et al. « L'amphotéricine B dans les émulsions lipidiques parentérales. Stabilité galénique des mélanges. Résultats préliminaires » 44:(5):1996;384-388. pathologie biologie.
22. Devoiselles J.M. « Les liposomes : structure, proprié tés et comportement in vivo » La Lettre de l'infectiologue. 1999;18-20.
23. Russo R., Nigro L.C., Minniti S., Gradoni L., Caldeira L., Davidson R.N. "Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (Ambisome)" J Infect. 32:1996;133-137.
24. Mac Bride M., Linney M., Claydon E.J., Weber J. "Visceral leishmaniasis following treatment with liposomal amphotericin B" Clin Infect Dis. 19:1994;362.
25. Torre-Cisneros J., Villanueva J.L., Kindelan J.M., Jurado R., Sanchez-Guijo P. "Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with HIV" Clin Infect Dis. 17:1993;625-627.
26. Davidson R.N., Di Martino L., Gradoni L., Giacchino R., Russo R., Gaeta G.B., et al. "Liposomal amphotericin B (Ambisome) in Mediterranean visceral leishmaniasis : a multi-centre trial" Quarterly Journal of Medicine. 87:1994;75-81.
27. Lazanas M.C., Tsekes G.A., Papandreou S., et al. "Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds, International congress on drug therapy in HIV infection" Scotland, AIDS. 6:(suppl):1992;s26.
28. Meyerhoff A. "US Food and Drug Administration of Approval of Ambisome (liposomal amphotericin B) for Treatment of Visceral Leishmaniasis" Clin Infect Dis. 28:1999;42-48.
29. Villanueva J.L., Alarcon A., Bernabeu-Wittel M., Cordero E., Prados D., Regordan C., et al. "Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly antiretroviral theapy" Eur J Clin Microbiol Infect Dis. 19:(10):2000;798-801.
30. Lafeuillade A.P., Chaffangeon E., Delbeke L., Quilichi R. "Maintenance Itraconazole for visceral leishmaniasis in HIV infection" A J Med. 92:1992;449.
31. Raffi F., Merrien D., Le pape P., Reliquet V. "Use of itraconazole/allopurinol combination for treatment of visceral leishmaniasis in a patient with AIDS" Clin Infect Dis. 21:1995;1338-1339.
32. Torrus D., Boix V., Massa B. "Fluconazole plus allopurinol in the treatment for visceral leishmaniasis" J Antimicrob Chemother. 37:1996;1042-1043. and coll.
33. Ribera E., Ocana I., De Otero J., et al. "Prophylaxis of visceral leishmaniasis in human immunodefiency virus infected patients" Am J Med. 100:1996;496-501.
34. Derouin F., Gangneux J.P. "Changing patterns of disease and treatment of parasitic opportunistic infections" Curr Opin Infect Dis. 11:1998;711-716.
35. Delgado J., Macias J., Pineda J.A., Corzo J.E., Gonzales-Moreno M.P., de la Rosa R., et al. "High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients" Am J Trop Med Hyg. 61:(5):1999;766-769.
36. Gangneux J.P. « Traitement de la leishmaniose viscérale : le point sur l'intérêt et les limites de la miltéfosine » Cahiers d'études et de recherches francophones/santé 2001.
37. Fisher C., Engel K., Bommer W. "Treatment of VL/HIV co-infected patients with oral miltefosine, Satellite symposium at the world Leish. II congress" 2001.
38. Kubar J., Marty P., Lelievre A., Quaranta J.F., Staccini P., Caroli-Bosc C., et al. "Visceral leihmaniasis in HIV positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts" AIDS. 12:(16):1998;2147-2153.
39. Berenguer J., Cosin J., Miralles P., Lopez J.C., Padilla B. "Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to higly active antiretroviral therapy" AIDS. 14:2000;2946-2948.
40. Laguna F., Torre-Cisneros J., Moreno V., et al. "Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodefiency virus" Clin Infect Dis. 21:1995;711-712.